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Abstract
Background: Cardiac troponin-I assays have been validated in horses.’High-sensitivity’ cardiac troponin assays are
now the standard in human cardiology. Objective: Appropriately validate the’high-sensitivity’ cardiac Troponin-T
(hscTnT) assay for clinical use in horses, establish reference intervals, determine the biological variation, and
demonstrate assay utility in selected clinical cases. Methods: Analytical validation of the Roche hscTnT assay included
within- and between-run precision, linear dose response, limit of quantitation (LoQ), stability, and comparison with
cTn-I (iSTAT). Reference intervals and biological variation were determined using adult, healthy, Non-Competition
Horses (N = 125) and Racing-Thoroughbreds (N = 178). HscTnT levels were measured in two horses with cardiac
pathology.
Results: The hscTnT demonstrates acceptable within-run (L1 = 6.5 ng/L, CV 14.9 %, L2 = 10.1 ng/L, CV 8.7 %,
L3 = 15.3 ng/L, CV 5.4 %) and between-run precision (L1 = 12.2 ng/L, CV 8.4 %, L2 = 57.0 ng/L, CV 8.4 %, L3 = 256.
0 ng/L, CV 9.0 %). The assay was linear from 3 to 391 ng/L. The LoQ was validated at 3 ng/L. Samples demonstrated
insignificant decay over freeze-thaw cycle. Comparison with cTnI assay showed excellent correlation (range: 8.0–3535.
0 ng/L, R2 = 0.9996). Reference intervals: The upper 95th and 99th percentile of the hscTnT population distribution
were 6.8 and 16.2 ng/L in Non-Competition Horses, and 14.0 and 23.2 ng/L in Racing-Thoroughbreds. Between-breed,
diurnal effect, and between-day variation was below LoQ. Two clinical cases with presumed cardiac pathology
had hscTnT levels of 220.9 ng/L and 5723.0 ng/L.
Conclusions: This benchmark study is the first to comply with CLSI guidelines, thus further establishing the
performance characteristics of the hscTnT assay, and reference intervals in healthy horses. Two clinical cases
demonstrated further the clinical utility of the assay.
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Background
As acknowledged in a recent joint consensus statement,
subtle or occult cardiac abnormalities are often difficult
to diagnose in horses [1]. Similarly, determining the im-
pact of any cardiovascular abnormality on present or fu-
ture performance, on rider or driver safety, and the
long-term effects on health and longevity can be prob-
lematic [1]. Early detection of cardiac pathologies would
provide the opportunity to recognize occult disease and
allow intervention prior to potentially more serious
outcomes such as cumulative cardiac damage or sudden
death.
One cardiac diagnostic tool that has been adopted for
use in veterinary medicine is the troponin assay. Of the
three troponin subunits, only cardiac Troponin-T
(cTnT) and cardiac Troponin-I (cTnI) have unique
amino acid sequences expressed as cardiac muscle-
specific isoforms, and are encoded by different genes
than the troponins expressed in skeletal muscle [2].
Since 2000, after an extensive search for a biomarker of
myocardial damage with sufficient analytical sensitivity
and specificity, troponin assays have been deemed the
test of choice for detection of acute myocardial injury
(AMI) in humans [3]. The assays have evolved through
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numerous generations, each of which has undergone
improvements in analytical performance. Troponin-I
and T assays with total imprecision ≤ 10 % at the 99th
percentile, and measurable normal values below the
99th percentile in at least 50 % of healthy individuals
are now classified as’high-sensitivity’ assays in humans
[4]. Older generation (‘non-hs’) troponin assay use in vet-
erinary medicine has been fairly widespread (reviewed by
Rossi et. al.) [5], and recently two reports use the hscTnT
assay [6, 7]. There are problems however, associated with
the clinical utility and application of the troponin assays
reported in the equine literature to date [6, 8–12].
These include: 1)- The general lack of appropriate ana-
lytical validation which can lead to erroneous interpret-
ation of results and subsequent designation of reference
ranges and threshold cut-off points. 2)- The large num-
ber of commercially available troponin assays that differ
from one another in terms of antibody-epitope specifi-
city and preclude direct comparison of results from
various studies. 3)- The use of older generation tropo-
nin assays that lack the sensitivity to detect occult or
potentially cumulative myocardial injury with the de-
gree of certainty needed in veterinary sports medicine
to explore the effects of subclinical myocardial damage.
With’high-sensitivity’ (5th generation) cardiac troponin
assays now available, our aim was to validate a human
automated’high-sensitivity’ cardiac Troponin-T (hscTnT)
Roche Diagnostics assay for use in horse plasma, and to
establish hscTnT reference intervals in adult, healthy,
Non-Competition Horses and Racing-Thoroughbreds
as presented in 2014 [13]. This validation study of the
Roche hscTnT assay for use in horses provides add-
itional valuable information by complying with the
recommendations of the Clinical and Laboratory Stan-
dards Institute (CLSI), the National Academy of Clin-
ical Biochemistry (NACB), and American Society of




Utilizing NCBI protein BLAST, Homo sapiens
cardiac Troponin-T amino acid residues of
epitopes recognized by capture MAb (M7)
(125–131:DRIERR) and detection MAb (M11.7)
(136–147:EQQRIRNEREKE) for the hscTnT
assay were compared to Equus caballus cardiac
and skeletal Troponin-T (Fig. 1).
2) Analytical validation of ‘high-sensitivity’ cardiac
Troponin-T assay
Roche Diagnostics cardiac Troponin-T
‘high-sensitivity’ assay, Cobas-e601 Analyzer
HscTnT assay, a 5th generation
electrochemiluminescence immunoassay, was
used on the Cobas-e601 Analyzer for analysis
of equine plasma samples, complying with
manufacturer’s instructions and CLS internal
quality controls systems. The manufacturer
determined the analytical characteristics for this
assay in accordance with the CLSI-EP17-A2
requirements. The analyzer was calibrated using
human cTnT standards supplied for use of the
hscTnT assay kit with human plasma.
Equine Troponin-T samples
Purified equine cardiac troponin used in
linearity and precision studies was obtained
from harvested equine myocardium as
previously described [18]. Plasma samples were
collected from all live horses, by jugular
venipuncture in 5 mL lithium-heparinized tubes.
Specimens were centrifuged at 2000 x g for
10 min, separated, frozen within 90 min, and
stored at−80 °C until batch analyzed. Degree of
hemolysis in all samples was assessed using the
serum indices instrument application on the
Roche Cobas-e601 platform2 and no specimen
Fig. 1 Amino acid sequence alignment of human cardiac Troponin-T (Type 2) adult isoform (cTnT) with horse (Equus caballus) cardiac Troponin-T
(Type 2) and homology with equine fast and slow skeletal muscle TnT using NCBI protein BLAST. Amino acid sequences include the epitope
regions against which the Roche, Cobas-e601 capture (M7) and detection (M11.7) antibodies are directed
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included in this study reached the hemolysis
threshold to be excluded.
Tissue specificity
Homogenates of cardiac and skeletal muscle
harvested from a healthy horse were prepared
as previously described [19] and subsequently
diluted.3 Dilutions used were within the linear
range of the hscTnT assay (cardiac: 100,000 fold,
skeletal muscle: 10,000 fold). The tissue
reactivities, expressed in ng/L wet weight, were
corrected for the dilution factor and are
presented as means ± SEM. Tissue Reactivity
(ng/g of wet tissue) = x hscTnT(ng/L) x dilution
factor ÷ weight of muscle sample(g) x dilution
of original homogenate muscle stock.
Linear dose response
N = 10 dilutions were prepared from purified
equine cardiac troponin stock by serial 1:2
dilution (from 1:100 to 1:0.2) using normal
equine plasma (hscTnT 3.28 ng/L) as diluent.
Triplicates of the resultant 11 samples (mean
hscTnT levels ranging from 8.0 to 3526.7 ng/L)
were analyzed to detect linearity over the
expected measurable range.
Assay precision
Within-run precision was evaluated by assaying
plasma samples from 3 horses containing 3
different previously determined (Roche
Diagnostics hscTnT assay) concentrations
of hscTnT (L1 = 6.5 ng/L, L2 = 10.1 ng/L,
L3 = 15.3 ng/L) 10 times in the same run.
Between-run precision was evaluated by
assaying prepared quality control samples
consisting of purified equine cardiac troponin
diluted with equine plasma at 3 levels
(L1 = 12.2 ng/L, L2 = 56.9 ng/L, L3 = 254.0 ng/L)
over 3 months and 10 different runs.
Functional sensitivity
The limit of quantitation (LoQ), defined as
the lowest analyte concentration that can be
reproducibly measured with a between-run CV ≤
10 %, was determined using 5 serial dilutions of
a stock, diluted, purified equine cardiac troponin
sample (hscTnT range 4-37 ng/L), and analysing
each dilution 5 times in 1 day.
Stability study
Stability of samples was tested at−80 °C for a
period of 24 months. Samples were measured at
the start and end of the testing period and the
average difference between the measured values
before and after storage was calculated. Criteria for
significant change: average difference of less than
2X the between-run standard deviation of the con-
trol level closest to the mean of samples measured.
Comparison study
Eleven diluted, purified equine cardiac troponin
samples of various increasing, known hscTnT
levels (previously determined using Roche
Diagnostics assay), were run in duplicate on the
iSTAT for equine cTnI analyte levels allowing for
comparison of hscTnT to older generation cTnI
results.
3) Reference intervals and biological variation of
hscTnT levels in healthy horses
Two subset populations were included in the
study and sampled by convenience (summer
2013): one group of Non-Competition Horses
with varying levels of routine physical activity and
a second group of Racing-Thoroughbred geldings
(Table 1). These populations provide reference
intervals of troponin levels for application of the
assay in sports medicine and exercise physiology
in addition to general application in clinical
cardiomyopathy cases. The study was approved
by the UCVM-Veterinary Sciences Animal Care
Committee and consent was obtained from the
animals’ owners.
Non-Competition Horses: Plasma samples were
taken from 125 non-performance, healthy horses
(ages 2–24; median 5 years, 69 geldings, 56
mares) represented by Quarter horses, Quarter
horse-crosses, Thoroughbreds, Warmbloods,
Draft horses, and Arabians.
Racing-Thoroughbreds: Plasma samples were
taken from 178 healthy, fit, actively competing
Thoroughbred Chuckwagon racing geldings
(ages 4–18; median 9 years) when the horses
were at rest in the morning prior to races.
For both populations, a physical examination
with heart auscultation was performed, and
Telemetric ECG was run stall-side and observed
for two minutes on all horses. Horses were
excluded for abnormal physical exam findings,
murmurs Grades III or greater, or any arrhythmia
other than second-degree atrioventricular block.
Horses had no known history of congenital or
acquired cardiac abnormalities.
Breed, diurnal and intra-individual variation
Evaluation of differences in hscTnT levels between
breed was determined by sample collection
from 25 horses representing Warmbloods,
Thoroughbreds, Quarter Horses, Arabians and
Draft Horses (5 horses of each breed). In addition,
diurnal and intra-individual variation was assessed
by sample collection from each horse every
morning and evening for 5 consecutive days.
4) Two selected case studies demonstrating clinical use
of hscTnT assay
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Case one
An 11 year old Thoroughbred Chuckwagon
gelding passed a mandatory racetrack
veterinary physical and lameness examination
on the morning of a race. He had no history
of previously administered medications. The
gelding later presented with near-collapse
event at the end of his race secondary to an
acute upper airway obstruction. The horse
was diagnosed stall-side, via auscultation, with
ventricular tachycardia immediately following
racing. Telemetric ECG was subsequently run
stall-side intermittently over 48 h. Plasma
hscTnT analyte levels were measured at 5 and
72 h following the event.
Case two
Fourteen year old Quarter Horse mare,
3 months pregnant, diagnosed with Neorickettsia
risticii by PCR and showing acute clinical signs
of cardiacimpairment, hypovolemic shock, and
systemic inflammatory response syndrome
(SIRS). Diagnostic testing was completed to
document the status of the patient in light of the
primary colitis pathology (venous hematologic,
blood chemistry, venous/arterial blood gas,
urinalysis, fractional excretion electrolyte ratios,
and fecal PCR). Cardiac evaluation included
physical examination, heart auscultation, 24-h
Telemetric ECG, and plasma hscTnT analyte
levels, but lacked cardiac ultrasonography (due
to logistical restrictions associated with isolation
hospitalization of a severe diarrhea case).
Following euthanasia, post-mortem examination
with selected histology was performed.
Statistical analysis
Linearity and LoQ were determined using Analyse-it soft-
ware5. Linearity of the assay was assessed by linear and
polynomial regression of the data and difference plot with
Total Error criteria. A Weighted Deming fit was used to
compare the fit between the hscTnT assay versus the cTnI
assay. The hscTnT population distributions were not nor-
mal using the Kolmogorov-Smirnov test. CLSI-28A3C
guidelines recommend Dixon’s and Tukey’s techniques for
outlier detection, however both are based on the assump-
tion that there is a normal distribution to the population
data [14]. Due to the severity of the right-skewed popula-
tion in this case, normalization of the data is unreliable
with transformation techniques such as Box-Cox trans-
formation. Consequently, visual inspection was selected as
a screening method and no outliers were detected in the
populations tested. The Mann-Whitney U test was utilized
to test the difference between the hscTnT levels in the
two horse sub-populations. Nonparametric methods,
complying with CLSI guidelines, were used for determin-
ation of the 95th and 99th percentiles and 90 % confidence
intervals for horses from each population.
Results
1) Analytical validation of ‘high-sensitivity’ cardiac
Troponin-T assay
Genetic homology
The epitopes detected by this commercial
hscTnT assay were conserved between humans
and horses with 100 % homology detected when
comparing human adult cardiac isoform cTnT
and equine cTnT [XP_005614937.1], while only
80 % [XP_005898432.1] and 56 %
Table 1 Comparison of ages, sexes, breeds and resting heparin plasma hscTnT concentrations in horses
Number 125 178 1 1
Non-Competition Horses Racing- Thoroughbreds Clinical Case I Clinical Case II
Median Age (Range) 5 (2–24) 9 (4–18) 11 14
Sexes 56 Mares,
69 Geldings
178 Geldings Gelding Mare
Breed(s) TB, QH, Drafts, Arabians, WB TB TB QH
Resting hscTnT
Mean (±SD), ng/L
3.6 (±2.1) 5.4 (±3.8) 221.0a 5723.0b
hscTnT Median, ng/L 3.0 4.0c N/A N/A
hscTnT Range, ng/L 3.0–17.0 3.0–24.0 N/A N/A
hscTnT 95 % URL






hscTnT 99 % URL






Comparison of ages, sexes, breeds and resting heparin plasma hscTnT concentrations from 303 apparently healthy horses (Non-Competition Horses and Racing-
Thoroughbreds) as well as two clinical cases
aHeparin plasma hscTnT sample taken 5 h after race-induced upper respiratory crisis event
bHeparin plasma hscTnT sample taken 41 h after initially presented to clinic
cIndicates a significant difference from Non-Competition Horses
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[XP_005896826.1] conservation was shown
between human adult cTnT and equine fast
and slow skeletal muscle respectively (Fig. 1).
Tissue specificity
Although there was some minimal detectable
reactivity from equine skeletal muscle in the
hscTnT immunoassay, hscTnT reactivity of
cardiac muscle was 256.2 times greater than that
in skeletal muscle (2.49 x107 and 9.75 x104 ng/g
wet weight respectively).
Linear dose response
While linear dose response was tested in the
range of 8–3527 ng/L, the assay was linear over
the hscTnT range of 3–391 ng/L (±2 ng/L or
5 %). Above 391 ng/L there is bias in the
regression with over-recovery of the analyte
demonstrated and even when the linearity
criteria are widened (to ±5 ng/L or 20 %) the
response is significantly non-linear (Fig. 2).
Assay precision
Within-run precision was: L1 = 6.5 ng/L, CV
14.9 %, L2 = 10.1 ng/L, CV 8.7 %, L3 = 15.3 ng/
L, CV 5.4 % and between-run precision was:
L1 = 12.2 ng/L, CV 8.4 %, L2 = 57.0 ng/L, CV
8.4 %, L3 = 256.0 ng/L, CV 9.0 % (Table 2). In
humans studies, the required precision is 10 %
within-run CV at the upper limit of normal
for the population. The horse specimens
have < 10 % CV at the levels closest to the
upper reference limit (99th percentile) in both
horse populations tested (Table 2).
Functional sensitivity (Limit of Quantitation)
The LoQ was validated at 3 ng/L (using a 10 % CV).
Stability study
The stability of the samples was excellent and
demonstrated slight, but not statistically
significant decrease in hscTnT analyte over the
average 24 month period between free-thaw
cycles (mean = 15.8 ng/L, average difference =
1.75 ng/L).
Comparison study
Comparison with cTn-I assay showed excellent
correlation (range: 8–3535 ng/L, R2 = 0.9996).
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Fig. 2 Plot of the linearity (triplicates of increasing concentrations of equine hscTnT) of the Roche, Cobas-e601 hscTnT assay. a, b Linear to a level
of 391 ng/L (±2 ng/L or 5 %). c, d Linearity run up to 3500 ng/L shows over-recovery
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results [hscTnT = (0.6 ± 0.0028)*(cTnI*1000)–
(11.5 ± 5.5)] (Fig. 3).
2) Biological variation of hscTnT levels in healthy horses
Reference interval determination of two subset
populations
HscTnT levels were different between the Non-
Competition Horses and Racing-Thoroughbreds
(p < 0.0001) (Table 1). As such, the populations
have been considered separately with respect
to upper reference limits. The upper 95th
(90 % CI) and 99th percentile of the population
distribution in Non-Competitive Horses
(N = 125) is 6.8 (90 % CI:6.0–12.0) and
16.2 ng/L and for Racing-Thoroughbreds
(N = 178) is 14.0 (90 % CI:10.0–18.0) and
23.2 ng/L, respectively (Table 1 and Fig. 4).
Lower reference limits are not clinically rele-
vant and are defined by the LoQ of the assay
(3 ng/L). 90 % CI could not be calculated
for the 99th percentile due N value restrictions
[14]. Measureable hscTn analyte levels
were obtained in 56.8 and 88.8 % for
Non-Competition Horses and Racing-
Thoroughbreds groups respectively.
Breed, diurnal and intra-individual variation in
Non-Competition Horse population
The assay did not have sufficient sensitivity to
assess between breed, diurnal effect and
between-day variation in Non-Competition
Horses partly due to low levels of hscTnT
(43.2 % of this reference population had average
values ≤ 3 ng/L) (Fig. 4).
3) Two selected case studies demonstrating clinical use
of hscTnT assay
Case one
The 11 year old TB Chuckwagon horse had
previously passed a veterinary physical and
lameness examination on the morning of the
race. The gelding finished the 0.5 mile race in
distress and presented immediately for
assessment. Examination showed cyanotic
mucous membranes and persistent tachycardia
(heart rate: 180 bpm). No cardiac murmurs
were noted on auscultation. Ventricular
tachycardia was confirmed on ECG that
converted to atrial fibrillation within 30 min
and spontaneously returned to sinus rhythm
with supportive therapy, but no conversion
treatment, within 12 h. The plasma sample
taken 5 h after the race for hscTnT had a value
of 221 ng/L; by 72 h the hscTnT value was
21 ng/L. Five weeks later, a standing and over-
Table 2 Precision of the hscTnT assay (Roche Diagnostics, Cobas-e601) for measuring equine plasma
Level 1 (L1) Level 2 (L2) Level 3 (L3)
Within-Run hscTnT
Mean (CV), ng/L
6.5 (14.9 %) 10.1 (8.7 %) 15.3 (5.4 %)
Between-Run hscTnT
Mean (CV), ng/L
12.2 (8.4 %) 57.0 (8.4 %) 256.0 (9.0 %)
Abbreviations: CV Coefficient of variation (in %)
Precision of the hscTnT assay (Roche Diagnostics, Cobas-e601) for measuring equine plasma hscTnT of three increasing levels (Level 1, 2, 3) on 10
separate occasions
Fig. 3 Correlation between cTn concentration in duplicates of
equine plasma samples of increasing levels as measured by the
Roche, Cobas-e601 hscTnT assay and the iSTAT cTnI assay. Correlation
between the 2 methods was high (range: 8–3535 ng/L, r = 0.9998).
Bias was evident in the Deming regression results [hscTnT = (0.6 ±
0.0028)*(cTnI*1000)–(11.5 ± 5.5)]
Fig. 4 Frequency distribution for hscTnT levels in Non-Competition
Horses and Racing-Thoroughbreds
Shields et al. BMC Veterinary Research  (2016) 12:104 Page 6 of 11
the-ground dynamic endoscopy during exercise
revealed a subepiglottic cyst with a severe retro-
version of the epiglottis during maximal effort.
Case two
The 14 year old QH mare was diagnosed with
Potomac Horse Fever, and SIRS (based on
tachycardia, fever, abnormal WBC count, as well
as severe elevations in lactate and toxic, tacky
mucous membranes) [20]. On admission the
mare had severe electrolyte imbalances,
endotoxemia (toxic neutrophils noted), acute
renal failure, and liver impairments (Table 3).
Despite emergency symptomatic treatment she
remained unstable and showed deterioration in
cardiovascular status (development of severe
bradyarrhythmia with intermittent long sinusal
pauses for up to 40 s, pale mucous membranes,
and weak pulses), as well as ongoing severe
diarrhea. A plasma sample taken for hscTnT
41 h following initial presentation measured
5723 ng/L. The mare was euthanized 44 h after
initial presentation and post mortem findings
included a moderately enlarged heart, failure of
left ventricle to contract completely after rigor
mortis, multifocal myocardial necrosis, and
congestion of the liver all suggestive of
myocardial function impairment.
Discussion
Adhering to the ASVCP guidelines based largely on the
strict CLSI guidelines, our results indicate that the
Roche Diagnostics cTnT assay (on the Cobas-e601
analyzer) can not only appropriately and adequately
measure plasma concentrations of equine cTnT, but it
can be classified as a’high-sensitivity’ immunoassay fit
for diagnostic use in horses. Meeting the CLSI guide-
lines, our study defined the reference intervals and de-
termined the upper 95th (90 % CI) and 99th percentile of
the population distribution in Non-Competitive Horses
(N = 125) is 6.8 (90 % CI: 6.0–12.0) and 16.2 ng/L and
for Racing-Thoroughbreds (N = 178) is 14.0 (90 % CI:
10.0–18.0) and 23.2 ng/L, respectively (Table 1, Fig. 4).
This study provides additional information key to inter-
preting hscTnT results in clinical context as compared
with recent reports [6, 7].
The epitopes detected by this hscTnT assay were con-
served between humans and horses with 100 % hom-
ology detected when comparing human adult cTnTand
equine cTnT (Fig. 1). Utilizing a series of validation ex-
periments according to industry guidelines, the assay
was challenged with detecting and measuring equine
cTnT [15, 16]. Homogenates of equine cardiac and skel-
etal muscle allowed for the determination of specificity
of the assay for hscTnT in cardiac versus skeletal
muscle. Cross-reactivity with the skeletal muscle isoform
of Troponin-T was minimal, indicating excellent assay
specificity for the cardiac isoform. Purified equine car-
diac troponin obtained from harvested equine myocar-
dium allowed for the determination of linearity explored
to levels exceeding the expected upper limit of the assay
according to ASVCP guidelines (up to 3526.7 ng/L) [16].
This method differed from that used in the Van Der
Vekens study [6] (in which diluted pooled samples from
clinical cases were used to assess linearity up to 1098.
8 ng/L) and allowed assessment of assay linearity at
higher analyte levels. Linearity of the assay in our study
was assessed by linear and polynomial regression of the
data and difference plot with Total Error criteria,
whereas the Van Der Vekens group used simple linear
regression analysis. Our work demonstrated good assay
linearity over the low range of cTnT concentrations, but
slightly over-recovers at high levels. However, 391 ng/L
is > 10 times our defined URLs, so linearity to this level
should confer good diagnostic sensitivity for distinguish-
ing sick from healthy populations. For an accurate quan-
titative determination for clinical purposes it is therefore
recommended to dilute specimens > 391 ng/L into the
linear range for future studies. No such dilutions were
performed on any clinical samples utilized throughout
this study.
The within-run and between-run precision values were
similar to those reported for measurement of human
cTnT and were within CLSI standards [21]. In humans
this assay has complied with the standards set forth by
the International Federation of Clinical Chemistry and
Laboratory Medicine to be defined as a’high-sensitivity’
assay [4]. Based on the same stringent criteria, our study
shows that this assay can be classified as a ‘high-sensitiv-
ity’ assay appropriate for diagnostic use in horses. Specif-
ically we showed that the total imprecision was ≤ 10 %
at the 99th percentiles for our two reference populations
(16.22 and 23.21 ng/L), and measureable cTn analyte
levels were obtained in 56.8 and 88.8 % for Non-
Competition Horses and Racing-Thoroughbreds groups
respectively.
It is critical for clinicians to understand certain basic
characteristics of assays, development of reference inter-
vals, and establishment of decision thresholds in order
to critically interpret troponin assay use reported in the
equine literature, and to successfully apply the assays
available for use in practice. The limit of quantitation
(LoQ) is the concentration above which quantitative re-
sults may be obtained with a specific degree of confi-
dence (ie.CV ≤ 10 %), and according to the CLSI
guidelines is recommended over the limit of detection
(LoD) for setting the lower reporting limits of a test for
clinical use. Importantly, only concentrations exceeding
an assay’s LoQ should be reported as a numerical value.
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RBC (x 1012/L) [6.4–10.4] 10.9 5.7
Hct (%) [30.0–47.0] 44 22.7
WBC (x 1012/L) [4.9–11.1] 13.6 7.1
NEU (x 1012/L) [2.5–6.9] 10.2 5.6
LYM (x 1012/L) [1.5–5.1] 2.4 1.1
MONO (x 1012/L) [0.2–0.6] 1.0 0.4
EOS (x 1012/L) [0.0–0.8] 0 0
BASO (x 1012/L) [0.0–0.1] 0.02 0.01
PLT (K/μL) [100–250] 238 196
Fibrinogen Manual (g/L) 7 5
CHEMISTRY
UREA (mmol/L) [3.6–8.9] > 46.4 40.6
CREA (μmol/L) [71–194] Too high to report Too high to report
CA (mmol/L) [2.6–3.2] 2.1 2.7
Total Protein (g/L) [56–79] 77 49
ALB (g/L) [19–32] 29 18
GLOB (g/L) [24–47] 48 31
AST (U/L) [100–600] 410 442
ALKP (U/L) [10–326] 195 134
GGT (U/L) [0–87] 17 20
TBIL (μmol/L) [0–60] 25 20
CK (U/L) [10–350] 505 361
LDH (U/L) [250–2070] 1694 2058
Na (mmol/L) [133–150] 104 147
K (mmol/L) [3.0–5.3] 2.3 2.4
Cl (mmol/L) [97–109] 79 116
HscTnT (ng/L) 5723
BLOOD GAS Venous Arterial
pH (7.35–7.45) 7.3 7.3
pCO2 (mmHg) [3.6–8.9] 40.4 38.4
PO2 (mmHg) 48 61
HCO3 (mmol/L) [25.0–30.0] 18 18.9
T CO2 (mmol/L) [24–32] 19 20
Base Excess [−5 to +5] −9 −8
sO2 (%) 77 89
Lactate (mmol/L) [0.3–1.5] 3.0 0.9
URINE
USG 1.009
Fraction of Excretion–Na (%) 40
Fraction of Excretion–Cl (%) 68
Fraction of Excretion–K (%) 157
Selected laboratory results for Case two, a 14 year old QH mare diagnosed with Potomac Horse Fever, and subsequent myocardial damage
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The LoQ can, for example, be significantly greater than
the LoD, as is reported in human plasma (LoD =3 ng/L,
but LoQ = 13.5 ng/L) [21]. All equine studies to date
using cardiac troponins mainly report values above man-
ufacturers’ defined LoDs, without verifying [6, 7, 9, 10],
or adhering to a determined functional sensitivity (LoQ)
[8]. The LoQ that we determined for equine plasma
using Roche’s hscTnT assay was validated at 3 ng/L
(10 % CV). It is possible that the true LoQ may be at a
level lower than 3 ng/L, but because the manufacturer
limits all reported values to 3 ng/L, lower levels could
not be validated. Additionally, the 10 % CV at 3 ng/L
which is lower than what was observed in within-run
precision Level 1 (14.9 % at 6.5 ng/L) may indicate that
at 3 ng/L the assay is approaching non-linear dose re-
sponse. Nevertheless, our results imply that any Roche
hscTnT assay value reported by the e601-Cobas instru-
ment is reliable for use in horse plasma.
The hscTnT assay reported values < 3 ng/L in 43.2 and
11.2 % of the Non-Competition Horses and Racing-
Thoroughbreds, respectively, which is similar to the val-
idation study in heathy humans (20.1 % at < 3 ng/L)
[21]. This limited the determination of biological vari-
ation, measured as intra-individual, inter-individual vari-
ation (between-breed), reference change values (RCVs),
and the index of individuality values. The ability of this
assay to function at these low concentrations (LoQ level)
is unique when compared to the only cTnI assay simi-
larly validated appropriately by ASVCP and CLSI stan-
dards for use in horses [8], and thus continues to show
promise for its’ ability to detect myocardial dysfunction
as well as the response of equine myocardium to various
exercise regimes. Comparison of hscTnT analyte levels
(measured on the Roche Diagnostics hscTnT assay) and
cTnI analyte levels (measured on the the iSTAT4) in
purified equine cardiac troponin samples, using a Dem-
ing regression, showed excellent correlation. Of note, a
Blant-Altman graph represents a bias plot and was not
used to compare the two assays as the numerical value
of any bias between hsTnT and cTnI is not clinically in-
terpretable when comparing the relative recoveries of
these two entirely different molecules. As human labora-
tories trend toward only using’high-sensitivity’ troponin
assays, the manufacturing of older generation assays
may discontinue.
While troponin assays’ use continues to grow in vet-
erinary fields clinicians must be aware that “all tropo-
nin assays are NOT created equal” [22]. In the
thorough review by Rossi et al. the use of troponin I as-
says in horses, as well as their associated limitations
and challenges, are highlighted [5]. The analysis and
standardization for cTnT is beneficially more straight-
forward than for cTnI. All assays for cTnT are mar-
keted by one manufacturer1, and instruments are
calibrated to the same reference material. It has been dem-
onstrated that Roche’s cTnT immunoassay detects binary
(cTnT-I and cTnT-C), ternary complexes (cTnT-I-C) of
troponin, and the free-cTnT form, as well as capably mea-
sures cTnT degradation by-products and phosphorylated-
cTnT in circulation [23]. Therefore, cTnT degradation
does not affect harmonization between different assays as
previously reported for the cTnI assays [24]. The effect of
EDTA in the cTnT assay seems to be minimal, whereas
differences between serum and plasma values have been
reported for a number of cTnI methods [4]. In human pa-
tient samples, cTnT appears to be very stable at room
temperature, 4 °C, and when repeatedly frozen and thawed
[21]. Similarly our study demonstrated excellent stability
of equine samples frozen, stored, and then thawed over
various time periods.
A goal for any assay is to establish decision thresholds
to distinguish among different groups. In human medi-
cine, an algorithm has been agreed upon to differentiate
healthy individuals from those suffering an AMI that in-
cludes the use of cTn assays but importantly includes
other criteria such as presence of clinical signs, and
other diagnostic imaging findings. Furthermore it rec-
ommends obtaining individuals’ cTn levels at a second
time point to increase the specificity of the assay and
promotes the use a delta cut-off instead of single diag-
nostic cut-off value [25]. Other factors, such as exercise
exposure, must be considered when interpreting the re-
sults of individual hscTnT analyte levels. This will be
particularly relevant when this assay is to be used on
performance horses, and thereby warrants further study
into the kinetics of hscTnT in the exercising horse.
Utilizing the ROC curve method, a calculated hscTnT
6.6 ng/L cut-off point for distinguishing healthy horses
from those with primary myocardial disease has been re-
cently published using the same Roche hscTnT assay [7].
Applying this cut-off point to our two defined reference
populations would imply 5 % of the Non-Competition,
and 22 % of the Racing-Thoroughbreds would be classi-
fied as having primary myocardial disease. This inter-
pretation is unlikely, and indicates caution must be used
when applying this cut-off point to various horse popu-
lations. The discrepancy may be partly explained by the
inclusion of only 20 healthy horses in the reference
population described by Van Der Vekens et al. [7], as
compared to our N = 125 Non-Competition and N = 178
Racing-Thoroughbred reference populations. Including a
minimum of 120 horses in each of our groups provided
populations for which reference intervals could be de-
fined by statistical methods in compliance with ASCVP
guidelines and provide better whole population normal
hscTnT level estimations. The use of only 20 horses in
the reference population used by Van Der Vekens et. al.
[7] led to a “tight” reference range, and significant
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overlap between their normal group and those classified
with primary myocardial disease. Their low cut-off point
was necessary to maintain acceptable sensitivity of the
assay, enabling it to distinguish between their two
groups, but is at the expense of possibly misclassifying
an unacceptably high number of healthy horses as dis-
eased. Their healthy horse group is most likely more
similar to our Non-Competition group of horses (than
our Racing-Thoroughbred group), but the authors did
not describe the use or fitness status of the members of
this group in which 10/35 were Trotters that may have
been in training or racing. Regardless, a hscTnT 6.6 ng/
L cut-off point differentiating healthy from those with
primary myocardial is likely more appropriately applied
to relatively sedentary horses rather than racing popula-
tions. Future studies may be warranted to determine car-
diac troponin cut-off points specific to racing horses.
The inclusion of only two case studies in our study is
few, but nevertheless demonstrate applications of the
hscTnT assay unique to those recently presented [7]. In
case one we report an adult Thoroughbred racing gelding
that presented for near collapse event, distress, clinical
signs of hypoxia (cyanosis), cardiac abnormalities identi-
fied on auscultation and ECG, and subsequently abnor-
mally high levels of hscTnT. The later over-the-ground
dynamic endoscopic confirmation of severe epiglottic
retroversion with a subepiglottic cyst and dorsal displace-
ment of the soft palate suggests a possible association be-
tween the clinical presentation of impaired gas exchange
and cardiac function as documented by elevations in the
myocardial biomarker hscTnT. We do however acknow-
ledge that a cardiac ultrasonographic assessment is miss-
ing, which limited the full characterization of his cardiac
status and the ability to determine the complete etiology
of his presentation. The elevated value detected 72 h later
demonstrates persistence of the biomarker cTnT further
emphasizing its clinical utility, as the practitioner can take
samples at time points slightly past onset of acute condi-
tion without missing the opportunity to detect myocardial
insult. Case two demonstrates a severe, multi-organ sys-
tem dysfunction likely related to SIRS and endotoxemia
associated with Potomac horse fever. Increases in cardiac
troponin have been previously reported in experimentally-
induced endotoxemia [9]. The diagnosis of myocardial
function impairment in this case was based on clinical
presentation, ECG monitoring, hscTnT levels, and post-
mortem evaluation but may have been strengthened by
completion of cardiac ultrasonography. Case two ex-
emplifies the level to which hscTnT may be seen clinic-
ally (5723 ng/L in this case as compared to the highest
level of 1341 ng/L recorded by the Van de Vekens
group in a horse with primary myocardial disease) [7].
Despite the fact that our linearity experiment showed
the assay has slight over-recovery of the hscTnT
analyte > 391 ng/L value, tracking the trend over time
in severely elevated values in cases such as this would
be of interest to the clinician with respect to case man-
agement and prognosis [11].
Additional limitations of our study include the abbre-
viated resting-ECG (2 min) on all horses included in the
two reference populations, as well as the absence of car-
diac ultrasonography. These methods reflect field-study
condition constraints. More thorough screening may
have further identified individuals that were inappropri-
ate for study inclusion as “healthy horses”. Our total
samples numbers included, and the absence of signifi-
cant outliers suggest however that the reference popula-
tions appropriately reflect more generalized healthy
populations.
Conclusions
In conclusion, this report has validated, according to the
rigorous recommendations of the CLSI, the only’high-
sensitivity’ troponin assay (Roche hscTnT, Cobas-e601)
for use in horses. The current literature is lacking many
of the validation experiments conducted in our study,
and thus the data published here significantly adds to
the conclusions of Van der Vekens et al. [6, 20]. In our
study reference intervals for the hscTn-T assay in
healthy adult Non-Competition and Racing Thorough-
bred horses were established, as were assay performance
characteristics, and sample collection protocols in
equine plasma samples. While the assay remains insuffi-
ciently sensitive to provide biological variation informa-
tion in mainly sedentary healthy horses at this time, it
will prove extremely useful for assessment of subtle
myocardial injury as well as the effects of exercise on
equine myocardium.
Endnotes
2Cobas-e601, Roche Diagnostics, Indianapolis, IN.
3Elecsys diluent multi-assay, Roche Diagnostics,
Indianapolis, IN.
5Televet-100, Engel Engineering, Offenbach, Germany.
4iSTAT-2, Heska Corp, Loveland, CO.
1Troponin-T hs, Roche Diagnostics, Indianapolis, IN.
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